bearish
SinoMab (中国抗体): Pipeline Concentrated on Autoimmune Therapy
675 Views19 Jul 2019 11:28
SinoMab, the first Hong Kong-headquartered biotech company coming to list on the SEHK, plans to raise USD100 to 200 million.
In this insight, we...
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 6-minute read)
Discussions
(Paid Plans Only)
x